Modus Therapeutics secures $15.7m for sickle cell disease drug development

Modus Therapeutics, a Swedish biotech firm specializing in sickle cell disease therapies, has successfully raised SEK 140 million ($15.76 million) in a funding round spearheaded ... Read More